share_log

Evercore ISI Group Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $3

Benzinga ·  Mar 22, 2023 11:35

Evercore ISI Group analyst Maneka Mirchandaney maintains MiNK Therapeutics (NASDAQ:INKT) with a Outperform and lowers the price target from $4 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment